ANXA7

Across TCGA pan-cancer cohorts, ANXA7 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ANXA7’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ANXA7 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ANXA7 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and PDAC are the cancer types where ANXA7 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANXA7 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	−0.349	<.001	11	view →
COAD	Male	All	−0.423	<.001	10	view →
PDAC	Male	II,III,IV	+0.370	<.001	8	view →
HNSC	Male	All	−0.101	.004	6	view →
LSCC	Male	II,III,IV	−0.077	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ANXA7–CCRCC

Open the CCRCC breakdown →